Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Dose-Dense Brentuximab Vedotin Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Is Highly Active for Second Line Treatment in Relapsed/Refractory Classical Hodgkin Lymphoma: Final Results of a Phase I/II Study

Blood (2020) 136 (Supplement 1): 16–18.

https://doi.org/10.1182/blood-2020-133763

Published: 2020

Journal Articles

Ibrutinib in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Final Results from a Prospective Phase II Study

Solomon A. Graf, MD, Ryan D. Cassaday, MD, Karolyn K. Morris, BA, Sanaz Behnia, MD, Qian Vicky Wu, PhD, Jenna M. Voutsinas, MPH, Ryan C. Lynch, MD, Elizabeth Krakow, MD, Heather A. Rasmussen, BS, Thomas R. Chauncey, MD PhD, Sandra Kanan, MSN, ARNP, Lorinda A. Soma, MD, Stephen D. Smith, MD, Ajay K. Gopal, MD

Blood (2019) 134 (Supplement_1): 1596.

https://doi.org/10.1182/blood-2019-126086

Published: 2019

Journal Articles

Ixazomib in Previously Untreated Indolent B-Cell Non-Hodgkin Lymphoma

Solomon A. Graf, MD, Ryan C. Lynch, MD, David G. Coffey, MD, Mazyar Shadman, MD MPH, Sandra Kanan, MSN, ARNP, Edward N. Libby, III, MD, Edus H. Warren, MD PhD, Colin Godwin, Ted Gooley, PhD, Jonathan R. Fromm, MD PhD, Ajay K. Gopal, MD

Blood (2018) 132 (Supplement 1): 5326.

https://doi.org/10.1182/blood-2018-99-117572

Published: 2018

Journal Articles

Outcomes of Patients with Large B-Cell Lymphomas and Progressive Disease Following CD19-Specific CAR T-Cell Therapy

Victor A. Chow, MD, Ajay K. Gopal, MD, David G. Maloney, MD PhD, Cameron J. Turtle, MBBS, PhD, Stephen D. Smith, MD, Mazyar Shadman, MD MPH, Ryan D. Cassaday, MD, Brian G. Till, MD, Yolanda D. Tseng, MD, Edus H. Warren, MD PhD, Andrei R. Shustov, MD, Manoj P. Menon, MD, Sandra Kanan, MSN, ARNP, Utkarsh H. Acharya, DO, Erin Mullane, DNP, Lindsay M. Hannan, MD MS, Jenna M. Voutsinas, MSc, Ted Gooley, PhD, Ryan C. Lynch, MD

Blood (2018) 132 (Supplement 1): 94.

https://doi.org/10.1182/blood-2018-99-110747

Published: 2018

Journal Articles

Pembrolizumab in Combination with Standard RCHOP Therapy for Previously Untreated Diffuse Large B-Cell Lymphoma

Stephen D. Smith, MD, Ryan C. Lynch, MD, Brian G. Till, MD, Andrew J. Cowan, MD, Qian V. Wu, PhD, Jenna M. Voutsinas, MSc, Mazyar Shadman, MD MPH, Katie Blue, Andrei R. Shustov, MD, Sandra Kanan, MSN, ARNP, Lauren Low, PA-C, Ryan D. Cassaday, MD, Jonathan R. Fromm, MD PhD, Ajay K. Gopal, MD

Blood (2018) 132 (Supplement 1): 1686.

https://doi.org/10.1182/blood-2018-99-119129

Published: 2018

Journal Articles

Ibrutinib Is Effective in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Results from a Prospective Phase II Study

Solomon A. Graf, MD, Ryan D. Cassaday, MD, Karolyn K. Morris, Heather A. Rasmussen, BS, Pamela S. Becker, MD, Thomas R. Chauncey, MD PhD, Sandra Kanan, MSN, ARNP, Lorinda A. Soma, MD, Stephen D. Smith, MD, Ajay K. Gopal, MD

Blood (2018) 132 (Supplement 1): 2954.

https://doi.org/10.1182/blood-2018-99-115476

Published: 2018

Journal Articles

Eligibility for Car-T Trials: An Analysis of Selection Criteria and Survival Outcomes in Chemorefractory DLBCL

Prathima Reddy, MD, Alexandra Sokolova, MD, Victor A. Chow, MD, Ryan C. Lynch, MD, Mazyar Shadman, MD MPH, Brian G. Till, MD, Andrei R Shustov, MD, Edus H. Warren, MD PhD, Manoj P. Menon, MD, Sandra Kanan, MSN, ARNP, Yolanda D. Tseng, MD, Ajay K. Gopal, MD, Stephen D. Smith, MD

Blood (2018) 132 (Supplement 1): 2911.

https://doi.org/10.1182/blood-2018-99-119794

Published: 2018

Journal Articles

Real World Utilization and Practice Patterns of Dose-Adjusted EPOCH for Aggressive B-Cell Lymphomas 2005-2015: Impact of Growth Factor Choice and Resultant Achieved Dose Level

Sandra Kanan, NP, RN, MSN, Ajay K Gopal, MD, Ryan D Cassaday, MD, Andrei R. Shustov, MD, Brian G. Till, MD, Andrew J. Cowan, MD, Mazyar Shadman, MD MPH, Warren Houston, MD PhD, Melinda Tran, Pharm.D, Oliver Press, Stephen Smith, MD

Blood (2016) 128 (22): 3577.

https://doi.org/10.1182/blood.V128.22.3577.3577

Published: 2016

Journal Articles

The Clonal Architecture of CXCR4mutations in Waldenstrom's Macroglobulinemia Shows Highly Variable Subclonal Distribution, and Multiple Mutations within Individual Patients Indicative of Targeted Genomic Instability

Blood (2015) 126 (23): 1486.

https://doi.org/10.1182/blood.V126.23.1486.1486

Published: 2015

Journal Articles

Defining the Incidence, Pathology and Clinical Outcomes of Kidney Disease Related to Waldenstrom's Macroglobulinemia and IgM MGUS

Josephine M. Vos, MD, Robert R Manning, Kirsten Meid, MPH, Joshua Gustine, MPH, Christopher J Patterson, MFA, Philip Brodsky, Sandra Kanan, NP, RN, MSN, Marie José Kersten, MD PhD, Steven P Treon, MD PhD, Jorge J Castillo, MD

Blood (2015) 126 (23): 3926.

https://doi.org/10.1182/blood.V126.23.3926.3926

Published: 2015

Journal Articles

Clinical Characteristics of Rituximab Intolerance in Patients with Waldenstrom's Macroglobulinemia

Sandra Kanan, NP, Kirsten Meid, MPH, Steven P Treon, MD MA, PhD, Jorge J. Castillo, MD

Blood (2014) 124 (21): 2610.

https://doi.org/10.1182/blood.V124.21.2610.2610

Published: 2014

Journal Articles

Incidence and Survival Outcomes of Secondary Malignancies Among Survivors of Waldenström Macroglobulinemia

Jorge J. Castillo, MD, Adam J. Olszewski, MD, Sandra Kanan, NP, Kirsten Meid, MPH, Zachary Hunter, Steven P Treon, MD MA, PhD

Blood (2014) 124 (21): 855.

https://doi.org/10.1182/blood.V124.21.855.855

Published: 2014

Journal Articles

Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia

Steven P. Treon, Christina K. Tripsas, Kirsten Meid, Sandra Kanan, Patricia Sheehy, Stacey Chuma, Lian Xu, Yang Cao, Guang Yang, Xia Liu, Christopher J. Patterson, Diane Warren, Zachary R. Hunter, Barry Turnbull, Irene M. Ghobrial, Jorge J. Castillo

Blood (2014) 124 (4): 503–510.

https://doi.org/10.1182/blood-2014-03-566273

Published: 2014

Journal Articles

Detection Of MYD88 L265P In Peripheral Blood Of Patients With Waldenström's Macroglobulinemia and IgM Monoclonal Gammopathy Of Undetermined Significance

Lian Xu, Zachary Hunter, Guang Yang, PhD, Yangsheng Zhou, MD, Xia Liu, MD, Yang Cao, MD, Robert Manning, Christopher Patterson, Christina K Tripsas, MA, Sandra Kanan, NP, Jiaji G Chen, Neil I Lindeman, MD, Steven Peter Treon, MD, MA, PhD

Blood (2013) 122 (21): 3024.

https://doi.org/10.1182/blood.V122.21.3024.3024

Published: 2013

Journal Articles

Carfilzomib, Rituximab and Dexamethasone (CaRD) Is Highly Active and Offers a Neuropathy Sparing Approach For Proteasome-Inhibitor Based Therapy In Waldenstrom’s Macroglobulinemia

Steven Peter Treon, MD, MA, PhD, Christina K Tripsas, MA, Kirsten Meid, MPH, Steven J Cropper, Patrick Mostyn, Diane Warren, Claudia E. Paba-Prada, MD, Christopher Patterson, Guang Yang, PhD, Zachary Hunter, Janet Kunsman, NP, Sandra Kanan, NP, Irene M. Ghobrial, MD

Blood (2013) 122 (21): 757.

https://doi.org/10.1182/blood.V122.21.757.757

Published: 2013

Journal Articles

A Prospective Multicenter Study Of The Bruton’s Tyrosine Kinase Inhibitor Ibrutinib In Patients With Relapsed Or Refractory Waldenstrom’s Macroglobulinemia

Steven Peter Treon, MD, MA, PhD, Christina K Tripsas, MA, Guang Yang, PhD, Yang Cao, MD, Lian Xu, Zachary Hunter, Steven J Cropper, Patrick Mostyn, Kirsten Meid, MPH, Diane Warren, Christopher Patterson, Gaurav Varma, MSPH, Jacob P. Laubach, MD, Claudia E. Paba-Prada, MD, Janet Kunsman, NP, Irene M. Ghobrial, MD, Sandra Kanan, NP, Ranjana H. Advani, MD, Maria Lia Palomba, MD

Blood (2013) 122 (21): 251.

https://doi.org/10.1182/blood.V122.21.251.251

Published: 2013

NARROW

Dose-Dense Brentuximab Vedotin Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Is Highly Active for Second Line Treatment in Relapsed/Refractory Classical Hodgkin Lymphoma: Final Results of a Phase I/II Study

Ibrutinib in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Final Results from a Prospective Phase II Study

Ixazomib in Previously Untreated Indolent B-Cell Non-Hodgkin Lymphoma

Outcomes of Patients with Large B-Cell Lymphomas and Progressive Disease Following CD19-Specific CAR T-Cell Therapy

Pembrolizumab in Combination with Standard RCHOP Therapy for Previously Untreated Diffuse Large B-Cell Lymphoma

Ibrutinib Is Effective in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Results from a Prospective Phase II Study

Eligibility for Car-T Trials: An Analysis of Selection Criteria and Survival Outcomes in Chemorefractory DLBCL

Real World Utilization and Practice Patterns of Dose-Adjusted EPOCH for Aggressive B-Cell Lymphomas 2005-2015: Impact of Growth Factor Choice and Resultant Achieved Dose Level

The Clonal Architecture of CXCR4mutations in Waldenstrom's Macroglobulinemia Shows Highly Variable Subclonal Distribution, and Multiple Mutations within Individual Patients Indicative of Targeted Genomic Instability

Defining the Incidence, Pathology and Clinical Outcomes of Kidney Disease Related to Waldenstrom's Macroglobulinemia and IgM MGUS

Clinical Characteristics of Rituximab Intolerance in Patients with Waldenstrom's Macroglobulinemia

Incidence and Survival Outcomes of Secondary Malignancies Among Survivors of Waldenström Macroglobulinemia

Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia

Detection Of MYD88 L265P In Peripheral Blood Of Patients With Waldenström's Macroglobulinemia and IgM Monoclonal Gammopathy Of Undetermined Significance

Carfilzomib, Rituximab and Dexamethasone (CaRD) Is Highly Active and Offers a Neuropathy Sparing Approach For Proteasome-Inhibitor Based Therapy In Waldenstrom’s Macroglobulinemia

A Prospective Multicenter Study Of The Bruton’s Tyrosine Kinase Inhibitor Ibrutinib In Patients With Relapsed Or Refractory Waldenstrom’s Macroglobulinemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only